Clinical Trial Search

Primary: Proportion of Women Who Benefited of Performing Upfront Sentinel Lymph Node (SLN) Biopsy Ductal Carcinoma in Situ — 51 Participants

Primary: Median Change in 6-month Tumor Volume Compared to Baseline Using Mammography — -5.0 change in tumor volume (mm) — p=0.07

Primary: Mean Total MRI Functional Tumor Volume (FTV) Change From Baseline to Month 3 (V3) — -1.93 cubic centimeters — p=<0.001

Primary: Proliferation (Ki67 IHC) in Ductal Breast Carcinoma In Situ (DCIS)

Primary: Number of Participants With Breast Cancer Recurrence, Including Recurrent DCIS and New Contralateral Tumours — 103; 120 Participants — p=0.33

Primary: Number of Participants With a Change in Ki-67 Level — 15; 5; 3 Participants — p=0.004

Primary: Verified Detection Rate for Metastasis — 5.9; 5.5 SUVMax

Primary: Difference Between Ki-67 Labeling Index in Tissue Samples Taken at Baseline and Post-treatment — -3.4; -5.1 percentage of 300 DCIS cells

Primary: Ipsilateral Invasive Breast Cancer, Ipsilateral Skin Cancer Recurrence, or Ipsilateral DCIS-Free Survival — 95.1; 96.1 percentage of patients event free

Primary: Change in Blood Concentrations — 4.2; -0.03 ng/ml

Primary: Percentage of Patients Free From Breast Cancer — 89.1; 93.1 percentage of participants event-free

Primary: Side Effects (Claim-based Measure), Including Lymphedema, Seroma, Wound Infection, or Pain — 534; 404; 23; 60 Participants — p=<.001

Primary: Percent Change in Proliferation as Measured by Ki-67

Primary: 18F-FES Uptake in DCIS — 1.43 SUV

Primary: Collect Data to Refine and Verify the Tumor Detection Algorithm. — 11.3 Percentage

Primary: Association Between Patient Characteristics and Three-Level Cluster of Treatment Intensity for Primary DCIS — 145; 115; 99; 0 Participants — p=<0.05

Primary: (Phase A Only) Selection of Dose of LUM015 to be Used in Future Breast Trials — 2.1; 4.7; 4.2 Ratio

Primary: Number of Participants Who Chose Active Monitoring (AM). — 28; 18 Participants

Primary: Endoxifen Concentrations in Participants Receiving Tamoxifen Citrate Dose of 20 mg or 40 mg Stratified by the Metabolizing CYP2D6 Genotypes — 8.4; 10.00; 7.10; 3.42 ng/mL

Primary: Test the Clinical Effectiveness of Concurrent Paclitaxel and Radiation in a Multiethnic Cohort

Primary: Change in Isothiocyanate in Urine Samples as Assessed at Baseline and After Completion of Study Therapy — 1.00; -0.05 µM/mM creatinine

Primary: Change in a Panel of Biomarkers (High-sensitivity C-reactive Protein [hsCRP], Lipid Profile, and Circulating Estrogens) From Baseline — -0.15; -54; -1; -81.5 mg/dl

Primary: The Tolerance of RIOP (Intra Operative Radiotherapy) in Patients With Delayed Local Recurrences, After a Second Conservative Treatment of Breast Cancer — 34; 19…

Primary: Local Control Rate for Follow-up Period of 5 Years. — 99 percentage of subjects

Primary: The Negative Predictive Value (PVV) of MRI

Primary: Success Rate in Removing Sentinel Lymph Nodes by Thoracoscopy — 31 participants

Primary: Maximum Tolerated Dose (MTD) — 10 milligrams

Primary: Pathologic Complete Response (pCR) — 18 percentage of participants

Primary: Local Recurrence — 3.1 percentage of participants

Primary: Percentage of Breast Cancer Cohort Participants With Confirmed Response Assessed Using RECIST v1.1 — 1 Participants